MetabolicIQ

The intelligence layer on India's metabolism.
GLP-1 · semaglutide · tirzepatide
Invite-only. 🇮🇳

[MetabolicIQ @Metabolic_IQ]

https://t.co/ntBS5hHnbu

#GLP1 #GLP1India #Tirzepatide #Semaglutide #MetabolicHealth

[MetabolicIQ @Metabolic_IQ]

@bryan_johnson Autonomous Health for the 0.01% starts here.
For the millions, it starts with structured monitoring of what they already have — daily intake, side effect patterns, hormonal response, body composition.
Different resolution.
Same philosophy: measure, don't guess.

[MetabolicIQ @Metabolic_IQ]

India will add millions of GLP-1 users this year.Most will track progress on a bathroom scale and call it health.

Scale weight ≠ fat loss.

Without tracking body composition, protein intake, hormonal response, and side effect patterns, you’re guessing, not managing.
Stand with science. Not with the scale.
#WorldHealthDay #GLP1India

[MetabolicIQ @Metabolic_IQ]

@ShivaniM_KC It scales when the system knows what day of the injection cycle the patient is on and adjusts everything around that. The answer exists. It’s just not inside a hospital.

[MetabolicIQ @Metabolic_IQ]

Solid Twitter Space tonight hosted by @AnshulGains — GLP-1 drugs: fact vs myth.
Two points that need more airtime in India:
@baxirahul - the drug opens the door but long-term discipline walks through it. The prescription is day 1, not the finish line.
@kamdar_j - stop stigmatising the drug or the person taking it. Lifestyle isn't a requirement, it's a prerequisite.
#GLP1 #GLP1India

[MetabolicIQ @Metabolic_IQ]

Most people think GLP-1 drugs just reduce hunger.
What’s actually happening: the drug is rewiring how your brain’s reward system values food. The pizza doesn’t taste worse. Your brain just stops obsessing over it 6 hours before dinner.
The neuroscience is catching up. But the lived psychological experience of millions of users — the identity shift, the grief of losing food as comfort, the silence where cravings used to be — that’s almost completely uncharted.

[MetabolicIQ @Metabolic_IQ]

Ask him if he’s seeing different side effect and compliance patterns on Day 1-2 post-injection vs Day 5-6 — and whether dosing protocols should account for the behavioral trough when drug levels drop and cravings return. Most patients think they’re failing. It’s just pharmacokinetics.
Tuning in tonight.

[MetabolicIQ @Metabolic_IQ]

@WSJ 50% dropout rate because patients are told what to take but never what to expect.
The drug works. The experience around it doesn’t.

[MetabolicIQ @Metabolic_IQ]

@nikolacupic Peptides went from biohacker niche to mainstream healthcare in under 3 years. The speed of adoption is outpacing the infrastructure around it — and that’s where the real opportunity lives.

[MetabolicIQ @Metabolic_IQ]

Indian GLP-1 users — what’s your daily protein intake? Before you Google it:

One bowl of dal = 9g
One roti = 3g
A full thali gets you maybe 25g

Your drug is working. Is your diet keeping up?

#GLP1 #GLP1India #Semaglutide #Tirzepatide #Ozempic #Mounjaro

[MetabolicIQ @Metabolic_IQ]

A powerful drug in the hands of a wellness clinic with zero screening is not healthcare, it’s ��cosmetic roulette”. The patients losing 8kg for a wedding aren’t being told what happens in Month 2 when they stop. Nobody’s planning the exit. That’s not @EliLillyandCo fault. That’s a system failure.

[MetabolicIQ @Metabolic_IQ]

@chiragbarjatya 13 out of 273 is exactly how it should work. The drug is powerful but only when the foundation is there first. Most programs skip the screening and hand out prescriptions like supplements. This is the responsible model.

[MetabolicIQ @Metabolic_IQ]

Your GLP-1 doesn’t work at the same strength all week.
Day 1-2: peak levels, appetite gone.
Day 5-7: trough, cravings return, diet slips.
Most users don’t know this cycle exists. They blame willpower on Day 6 when it’s just pharmacokinetics.
#GLP1 #Semaglutide #GLP1India

[MetabolicIQ @Metabolic_IQ]

@newstart_2024 Rogan’s point about body fat percentage going UP after losing 20lbs is the stat that should terrify people. You can lose weight and get metabolically worse at the same time. The scale is lying to most GLP-1 users right now.

[MetabolicIQ @Metabolic_IQ]

@Polymarket $1.8B selling prescriptions. Zero patient monitoring. Zero outcome tracking. The prescription is the easy part. What happens after the patient gets the drug is where health outcomes are actually decided. Medvi solved access. Nobody’s solved what comes next.

[MetabolicIQ @Metabolic_IQ]

@kamleshkhunti @AskDrShashank @EASDnews @ADA_DiabetesPro @APPG_Diabetes @AmDiabetesAssn @DiabetesUK @ABCDiab That 0.57 HR at lifestyle score 6-8 + GLP-1 is the number that should end the “drug vs lifestyle” debate permanently. Neither wins alone. Together they’re almost halving MACE risk. The real question is who’s helping patients actually hit a 6-8 lifestyle score while on the drug.

[MetabolicIQ @Metabolic_IQ]

@CMEINDIA1 Ozempic facies is the visible symptom. The invisible one — lean mass loss from inadequate protein on suppressed appetite. Most patients don’t know they’re losing muscle until the face changes. Structured nutrition monitoring catches it months earlier.

[MetabolicIQ @Metabolic_IQ]

“High-risk clinical transition rather than a treatment endpoint” this framing needs to be standard. The behavioral anchor in Phase 3 is where most patients are left completely unsupported. Structured daily monitoring during that transition is what turns discontinuation from a cliff into a ramp.

[MetabolicIQ @Metabolic_IQ]

All of this is spot on.The missing layer, who’s helping patients actually execute the Big 4 between endo visits? Diet, exercise, sleep, mental health are easy to list.Tracking them daily alongside your injection cycle while appetite is suppressed and your body is changing, that’s the hard part nobody’s solving yet.

[MetabolicIQ @Metabolic_IQ]

FDA just approved the first oral GLP-1 pill for weight loss.
Injectable to oral. Patented to generic. Expensive to affordable.
Access keeps expanding. Monitoring stays at zero.
The delivery method changed. The problem didn’t.
#GLP1 #Semaglutide #GLP1India

[MetabolicIQ @Metabolic_IQ]

Lost 15kg on tirz. Switched to sema 0.25mg. Regained all of it. The drugs work - the system around them doesn’t. No structured monitoring during the switch, no dose equivalence mapping, no behavioral support between appointments.The patient did everything right. The pathway failed her.